Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $111,685 | $65,933 | $141,368 | $283,810 |
| - Cash | $56,998 | $51,662 | $34,507 | $73,570 |
| + Debt | $3,175 | $3,384 | $3,701 | $3,946 |
| Enterprise Value | $57,862 | $17,655 | $110,562 | $214,186 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$198 | -$197 | -$201 | -$203 |
| % Margin | – | – | – | – |
| EBITDA | -$18,906 | -$32,892 | -$33,934 | -$34,450 |
| % Margin | – | – | – | – |
| Net Income | -$17,058 | -$30,733 | -$31,918 | -$31,227 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.36 | -0.65 | -0.68 | -0.69 |
| % Growth | 44.6% | 4.4% | 1.4% | – |
| Operating Cash Flow | -$17,365 | -$25,535 | -$29,423 | -$27,720 |
| Capital Expenditures | $0 | $0 | $9 | -$9 |
| Free Cash Flow | -$17,365 | -$25,535 | -$29,414 | -$27,729 |